1.Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO et al: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology 2018, 4(11):1553–1568.
2.Kumarakulasinghe NB, van Zanwijk N, Soo RA: Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology (Carlton, Vic) 2015, 20(3):370–378.
3.Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A, Berezovski MV, Kichkailo AS: Current and Prospective Protein Biomarkers of Lung Cancer. Cancers 2017, 9(11).
4.Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J et al: Paraneoplastic thrombocytosis in ovarian cancer. The New England journal of medicine 2012, 366(7):610–618.
5.Pedersen LM, Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. The European respiratory journal 1996, 9(9):1826–1830.
6.Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C et al: Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thrombosis and haemostasis 2003, 89(6):1098–1106.
7.Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K: Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. Journal of surgical oncology 2012, 106(7):887–891.
8.Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ: Prognostic value of thrombocytosis in renal cell carcinoma. The Journal of urology 2006, 175(3 Pt 1):859–863.
9.Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015, 33(9):983–991.
10.Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H: Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiation oncology (London, England) 2010, 5:47.
11.Wu YF, Chu SC, Chang BS, Cheng YT, Wang TF: Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy. BioMed research international 2019, 2019:1263050.
12.Ye SL, Li XY, Zhao K, Feng T: High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: A cohort study. Medicine 2017, 96(15):e6472.
13.Sylman JL, Mitrugno A, Tormoen GW, Wagner TH, Mallick P, McCarty OJT: Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. Convergent science physical oncology 2017, 3(2).
14.Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. European journal of cancer (Oxford, England: 1990) 2011, 47(17):2633–2641.
15.Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P: Inflammation-mediated promotion of invasion and metastasis. Cancer metastasis reviews 2010, 29(2):243–248.
16.Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, Horgan PG, McMillan DC: Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. British journal of cancer 2013, 109(1):24–28.
17.Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, Lee CK: Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British journal of cancer 2013, 109(1):147–153.
18.Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C et al: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. British journal of cancer 2013, 109(2):416–421.
19.Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Hirakawa K: A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer research 2013, 33(8):3291–3294.
20.Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A: Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pacific journal of cancer prevention: APJCP 2013, 14(9):5237–5242.
21.Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. Journal of gynecologic oncology 2012, 23(4):265–273.
22.Wang TF, Chu SC, Lee JJ, Yang GG, Huang WH, Chang ET, Low T, Wu YF, Kao RH, Lin CB: Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. Asia-Pacific journal of clinical oncology 2017, 13(4):304–313.
23.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 2015, 136(5):E359–386.
24.Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y et al: Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine 2009, 361(10):947–957.
25.Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai C-M, Boyer M et al: Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology 2013, 31(27):3327–3334.
26.Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 2004, 304(5676):1497–1500.
27.Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nature reviews Cancer 2007, 7(3):169–181.
28.Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS: Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Journal of clinical pathology 2011, 64(11):947–952.
29.Zhou X, Cai L, Liu J, Hua X, Zhang Y, Zhao H, Wang B, Li B, Gai P: Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. Oncology letters 2018, 16(1):362–370.
30.Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, Yang PC, Shih JY: Survival of lung adenocarcinoma patients with malignant pleural effusion. The European respiratory journal 2013, 41(6):1409–1418.
31.Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ: Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010, 65 Suppl 2:ii32–40.
32.Chen SF, Lin YS, Jao SW, Chang YC, Liu CL, Lin YJ, Nieh S: Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade. PloS one 2013, 8(5):e54659.
33.Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, Hayakawa H, Minami D, Sato A, Tabata M et al: Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung cancer (Amsterdam, Netherlands) 2013, 81(3):435–439.
34.Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH: Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung cancer (Amsterdam, Netherlands) 2014, 84(2):196–202.
35.Yovino S, Grossman SA: Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS oncology 2012, 1(2):149–154.
36.Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R: Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 2009, 115(5):1091–1099.
37.Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochemical and biophysical research communications 1998, 253(3):797–803.
38.Maraz A, Furak J, Varga Z, Kahan Z, Tiszlavicz L, Hideghety K: Thrombocytosis has a negative prognostic value in lung cancer. Anticancer research 2013, 33(4):1725–1729.
39.Kim M, Chang H, Yang HC, Kim YJ, Lee CT, Lee JH, Jheon S, Kim K, Chung JH, Lee JS: Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World journal of surgical oncology 2014, 12:37.
40.Meriggi F, Codignola C, Beretta GD, Ceresoli GL, Caprioli A, Scartozzi M, Fraccon AP, Prochilo T, Ogliosi C, Zaniboni A: Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy. Tumori 2017, 103(5):443–448.
41.Phan TT, Ho TT, Nguyen HT, Nguyen HT, Tran TB, Nguyen ST: The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. International journal of general medicine 2018, 11:423–430.
42.Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883–899.